Filtered Trial for Telmisartan 40mg Non-responder

Exclusion Criteria

• •1. Taking four or more anti-hypertensive medications
• •2. Secondary hypertension
• •3. Mean seated diastolic blood pressure (DBP) \> 114 mmHg and/or mean seated systolic blood pressure (SBP) \> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \< 90 mmHg at Visit 3.
• •4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias
• •5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV
• •6. History of myocardial infarction or cardiac surgery within last 6 months
• •7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months
• •8. History of unstable angina within last 3 months
• •9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
• •10. History of stroke or transient ischemic attack within last 6 months
• •11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy
• •12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors
• •13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs
• •14. Hepatic and/or renal dysfunction
• •15. Diagnosed biliary atresia or cholestasis
• •16. Hyperkalemia
• •17. Dehydration
• •18. Sodium deficiency
• •19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)
• •20. Patients who cannot change to the restricted administration and dosage during study period
• •21. Pre-menopausal women who meet any one of the following 1 - 3:
• •* Pregnant or possibly pregnant (1)
• •* Nursing (2)
• •* Desire to become pregnant during study period (3)
• •22. Drug or alcohol dependency
• •23. Complication of malignant tumour or a disease requiring immunosuppressants
• •24. Compliance of \< 80% or \> 120% during the run-in period
• •25. Receiving any investigational therapy within 3 months
• •26. Judged to be inappropriate by the investigator or the sub-investigator